Clinical Trial Command Center

V0 AI Agent Platform | ClinicalTrials.gov Integrated

FDA 21 CFR Part 11 Compliant

Phase 1/2RECRUITINGNCT05094336

AMG 193 in Subjects With MTAP-Deleted Solid Tumors

PRMT5 Inhibitor (MTA-Cooperative) | MTAP-Deleted Advanced Solid Tumors

Enrollment

287/ 450

63.8% complete

Active Sites

Global locations

Study Arms

Dose cohorts

Est. Completion

Jun 2026

Primary endpoint

ClinicalTrials.gov

COMPLIANT

98.7%

ICH

COMPLIANT

99.2%

FDA

COMPLIANT

97.8%

HIPAA

COMPLIANT

99.5%

Study Arms Performance

Dose escalation and expansion cohorts

Arm A

300mg QD

Subjects

34.7%

ORR

Enrolling

Arm B

450mg QD

Subjects

41.2%

ORR

Enrolling

Arm C

600mg QD

Subjects

38.9%

ORR

Enrolling

Expansion

RP2D

Subjects

42.8%

ORR

Active

Key Milestones

FPFV

Nov 15, 2021

RP2D Determination

Mar 22, 2024

Expansion Enrollment 50%

Jan 10, 2025

Interim Analysis

Jun 30, 2025

Primary Completion

Jun 30, 2026

DNA-Lang Clinical v2.1Lambda-Phi: 0.7734Agent Coherence: STABLE

ClinicalTrials.gov ID: NCT05094336Last System Update: 2/26/2026, 3:43:47 AM